What is a stock summary page? Click here for an overview.
Business Description
Spero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US84833T1034
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.31 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -6.67 | |||||
| Beneish M-Score | 10.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 72.4 | |||||
| 3-Year EBITDA Growth Rate | 22 | |||||
| 3-Year EPS without NRI Growth Rate | 24.5 | |||||
| 3-Year FCF Growth Rate | 40.7 | |||||
| 3-Year Book Growth Rate | -32.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.76 | |||||
| 9-Day RSI | 26.12 | |||||
| 14-Day RSI | 30.88 | |||||
| 3-1 Month Momentum % | -30.05 | |||||
| 6-1 Month Momentum % | -40.81 | |||||
| 12-1 Month Momentum % | -54.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | |||||
| Quick Ratio | 2.19 | |||||
| Cash Ratio | 1.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19 | |||||
| Shareholder Yield % | 3.52 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -264.58 | |||||
| Net Margin % | -250.28 | |||||
| FCF Margin % | -85.57 | |||||
| ROE % | -86.73 | |||||
| ROA % | -45.98 | |||||
| ROIC % | -114.18 | |||||
| 3-Year ROIIC % | 96.61 | |||||
| ROC (Joel Greenblatt) % | -1991.32 | |||||
| ROCE % | -69.31 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.21 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.18 | |||||
| EV-to-EBITDA | 0.18 | |||||
| EV-to-Revenue | -0.49 | |||||
| EV-to-Forward-Revenue | 0.1 | |||||
| EV-to-FCF | 0.57 | |||||
| Price-to-GF-Value | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 0.81 | |||||
| Earnings Yield (Greenblatt) % | 555.56 | |||||
| FCF Yield % | -72.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spero Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27.396 | ||
| EPS (TTM) ($) | -1.27 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 24.5 | ||
| 14-Day RSI | 30.88 | ||
| 14-Day ATR ($) | 0.053874 | ||
| 20-Day SMA ($) | 0.76502 | ||
| 12-1 Month Momentum % | -54.47 | ||
| 52-Week Range ($) | 0.5568 - 1.75 | ||
| Shares Outstanding (Mil) | 55.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spero Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spero Therapeutics Inc Frequently Asked Questions
What is Spero Therapeutics Inc(SPRO)'s stock price today?
The current price of SPRO is $0.63. The 52 week high of SPRO is $1.75 and 52 week low is $0.56.
When is next earnings date of Spero Therapeutics Inc(SPRO)?
The next earnings date of Spero Therapeutics Inc(SPRO) is 2025-05-15 Est..
Does Spero Therapeutics Inc(SPRO) pay dividends? If so, how much?
Spero Therapeutics Inc(SPRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers